SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Human & Experimental Toxicology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Talbot, R.J.
Right arrow Articles by Day, J.P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Talbot, R.J.
Right arrow Articles by Day, J.P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Inter-subject variability in the metabolism of aluminium following intravenous injection as citrate

R.J. Talbot

Biomedical Research, AEA Technology, 364 Harwell, Didcot, Oxon, OX11 ORA, UK

D. Newton

Biomedical Research, AEA Technology, 364 Harwell, Didcot, Oxon, OX11 ORA, UK

N.D. Priest

Biomedical Research, AEA Technology, 364 Harwell, Didcot, Oxon, OX11 ORA, UK

J.G. Austin

Biomedical Research, AEA Technology, 364 Harwell, Didcot, Oxon, OX11 ORA, UK

J.P. Day

Department of Chemistry, University of Manchester, Manchester M13 9PL, UK

1 Six healthy male volunteers received intravenous injec tions of 26Al as citrate. Accelerator mass spectrometry and {gamma}-ray spectrometry were used to determine levels of the tracer in blood and excreta at times up to 5-6 d.

2 There was a rapid clearance from blood (mean 2% of injection remaining after 1 d) and major loss in urine (59% up to 1 d), but 27 ± 7 (s.d.)% was retained in the body at 5 d. Faecal excretion was negligible (1% up to 5 d).

3 The mean results accord with the early metabolic pat tern in the single subject of a previous, more extensive study, who had retained 4% of the injection after 3 y. Together, the two studies point to the likelihood of large inter-subject differences in the long-term accumulation of dietary aluminium by populations receiving a given level of daily intake.

Key Words: variability • metabolism • aluminium • citrate • neurotoxicity (Received 27 May 1994 • accepted 20 September 1994)

Human & Experimental Toxicology, Vol. 14, No. 7, 595-599 (1995)
DOI: 10.1177/096032719501400707
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 BrainHome page
R. K. Gherardi, M. Coquet, P. Cherin, L. Belec, P. Moretto, P. A. Dreyfus, J.-F. Pellissier, P. Chariot, and F.-J. Authier
Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle
Brain, September 1, 2001; 124(9): 1821 - 1831.
[Abstract] [Full Text] [PDF]


Advertisement